Seeking Alpha

Orexigen Therapeutics (OREX +8.3%) says it reached an agreement with the FDA on details of the...

Orexigen Therapeutics (OREX +8.3%) says it reached an agreement with the FDA on details of the design and planned analysis for a trial of its diet drug Contrave. The objective of the trial is to demonstrate that Contrave doesn't increase the risk of major adverse cardiovascular events.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|